Allogene Therapeutics, Inc. (ALLO) Stock
Fundamentals
Recent news

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
ALLO

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
ALLO

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO

Allogene Therapeutics Q2 Earnings Call Highlights
Allogene Therapeutics Q2 Earnings Call Highlights
ALLO
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
ALLO

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
ALLO

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO

Allogene Therapeutics Q2 Earnings Call Highlights
Allogene Therapeutics Q2 Earnings Call Highlights
ALLO

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
ALLO

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO

Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
ALLO

Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics Q1 Earnings Call Highlights
ALLO

Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics ends China cell therapy deal with Overland
ALLO

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
ALLO
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman | 1949 |
| Dr. Zachary J. Roberts M.D., Ph.D. | President, CEO & Director | 1978 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 1977 |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder & Director | 1960 |
| Mr. Geoffrey M. Parker | Executive VP & CFO | 1965 |
| Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer | 1977 |
| Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary | 1963 |
| Ms. Susan R. Lundeen | Chief People Officer | 1966 |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | — |
| Ms. Annie Yoshiyama | SVP & Corporate Controller | 1984 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.2 | -29.7 | -1.3 | -18.1 | ||||||||
| 2022 | -25.1 | -23.0 | +6.1 | -11.6 | -13.0 | +48.1 | +12.8 | +13.1 | -24.1 | -3.5 | -6.7 | -32.9 |
| 2023 | +34.0 | -20.3 | -22.1 | +6.7 | -5.1 | -6.6 | +0.0 | -18.8 | -21.7 | -9.0 | -17.0 | +27.4 |
| 2024 | -2.8 | +32.3 | -9.5 | -37.0 | -14.4 | -7.2 | +18.5 | |||||
| 2026 | +71.6 | -7.9 | -16.8 | +0.9 | -3.3 | -10.9 | +8.7 | -17.1 |



